Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US payer's proposed class action hits Forest on Celexa promotion

This article was originally published in Scrip

Executive Summary

Forest, Pfizerand Warner-Lambert (acquired by Pfizer in 2000) have been hit with a proposed class action by a third party, which alleges that from 1998 through at least 2005 the companies engaged in a "widespread campaign" to illegally market the SSRI antidepressants Celexa (citalopram) and Lexapro (escitalopram), for off-label use in paediatric patients. Forest had a co-promotion agreement for Celexa with Warner-Lambert.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000821

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel